CDA | Evidence Driven
CDA | Evidence Driven

Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details

Details

Files
Generic Name:
Crizotinib
Project Status:
Complete
Therapeutic Area:
ROS1-positive advanced non-small cell lung cancer (NSCLC)
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Xalkori
Project Line:
Reimbursement Review
Project Number:
PC0151-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
200 mg & 250 mg
Tumour Type:
Lung
Indications:
ROS1-positive advanced Non-Small Cell Lung Cancer
Funding Request:
As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC)
Sponsor:
Cancer Care Ontario Lung Cancer Drug Advisory Committee
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – pERC Final Recommendation Final Recommendation May 23, 2019 View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Final Economic Guidance Report Guidance Reports May 23, 2019 View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Final Clinical Guidance Report Guidance Reports May 23, 2019 View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – pERC Initial Recommendation Initial Recommendation May 3, 2019 View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – PAG Feedback on Initial Recommendation Feedback May 23, 2019 View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Manufacturer Feedback on Initial Recommendation Feedback May 23, 2019 View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Patient Advocacy Group Feedback on Initial Recommendation Feedback May 23, 2019 View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Clinician Feedback on Initial Recommendation Feedback May 23, 2019 View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Patient Advocacy Group COI Declarations COI Declarations May 23, 2019 View PDF
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Clinician COI Declarations COI Declarations May 23, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : June 7, 2019